The specific molecular mechanism is still unclear 4
And this often is a form factor as you outlined or it could be dosing dynamics of a patient is not getting the outcome that theyre hoping for, are they experiencing side effects that are intolerable
Recently, the first clinical trial to show the benefit of AOMs in ORC outcomes was published
Iron (if deficient): To support oxygen transport
GLP-1 class safety monitoring should include awareness of these important risks: Pancreatitis : Patients should promptly report severe abdominal pain, with or without vomiting Gallbladder disease : Report symptoms of biliary colic or cholecystitis Acute kidney injury : Maintain adequate hydration, especially if experiencing nausea/vomiting Hypoglycemia : Increased risk when used with insulin or sulfonylureas Suicidal ideation : For patients using Wegovy or Zepbound, monitor for mood changes Patients should be counseled to report any neck swelling, difficulty swallowing, persistent hoarseness, or palpable thyroid nodules, as these warrant evaluation regardless of GLP-1 use
Milk Thistle : Nature's helper for boosting your glutathione levels